Recombinant Human Erythropoietin Alfa
Stroke, Acute
Max-Planck-Institute of Experimental MedicinePhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
133 Active assets in the Stroke, Acute cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aggrenox Boehringer Ingelheim | Phase 4 | BBB |
INCOBOTULINUMTOXINA Parc de Salut Mar | Phase 4 | BBB |
ATENOLOL Northern California Institute of Research and Education | Phase 4 | BBB |
Dextromethorphan University of Florida | Phase 4 | BBB |
Tenecteplase Assistance Publique - Hôpitaux de Paris | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Recombinant Human Erythropoietin Alfa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →